Comprehensive I-Human Advanced DDX Case
Study: Margaret Wilson – Progressive Dyspnea,
Volume Overload, and Heart Failure with
Reduced Ejection Fraction in a 60-Year-Old
Female With Complete Solutions EXAM with
Questions and Answers/Plus a Rationale
Updated 2026 A+/Instant Download PDF
EXAM COVERAGE
1. Pathophysiology and Epidemiology of HFrEF
2. Clinical Presentation and Physical Examination Findings
3. Diagnostic Modalities: Labs, Imaging, and Hemodynamics
4. Evidence-Based Pharmacotherapy (GDMT)
5. Differential Diagnosis and Comorbidity Management
6. Acute Decompensation and Fluid Management
7. Long-term Prognostic Indicators and Risk Stratification
8. Patient Education and Self-Management Strategies
9. Arrhythmia Risk and Device Therapy Integration
10. Interprofessional Care Coordination
,1. A 60-year-old female presents with progressive orthopnea and paroxysmal nocturnal dyspnea.
Physical examination reveals jugular venous distension (JVD) to 12 cm, a displaced apical
impulse, and a third heart sound (S3). Which of the following best explains the presence of the
S3 in this patient?
A. Atrial kick against a stiff, non-compliant ventricle
B. Rapid ventricular filling into a dilated left ventricle with high filling pressures
C. Turbulent blood flow across a restricted mitral valve annulus
D. Early systolic ejection into a dilated aorta
Answer: B
CORRECT ANSWER : B
Rationale: The S3 heart sound is highly specific for volume overload and high left ventricular
end-diastolic pressures in the setting of systolic dysfunction. Option A refers to an S4, which
indicates diastolic dysfunction. Option C refers to murmurs associated with mitral stenosis, and
option D describes flow patterns not associated with S3.
2. Laboratory testing reveals an NT-proBNP of 4,500 pg/mL. How should the provider interpret
this biomarker in the context of the patient's acute presentation?
A. It confirms a primary pulmonary diagnosis of COPD exacerbation
B. It is a non-specific marker that requires immediate cardiac catheterization
C. It strongly supports a diagnosis of decompensated heart failure due to elevated
myocardial stretch
D. It is only diagnostic if the patient has a history of coronary artery disease
Answer: C
CORRECT ANSWER : C
Rationale: NT-proBNP is a gold-standard biomarker for evaluating cardiac wall stress and
volume overload. While elevation can occur in other conditions, a value of 4,500 is highly
suggestive of heart failure in this clinical context. Option A is incorrect because BNP would
typically be low in primary pulmonary disease, and D is incorrect as it is not limited to patients
with known CAD.
3. The patient is diagnosed with HFrEF (EF 30%). Which medication is indicated as foundational
therapy for its proven benefit in reducing mortality and hospitalizations in HFrEF?
, A. Calcium Channel Blockers (non-dihydropyridines)
B. Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
C. High-dose short-acting loop diuretics
D. Oral nitrates as monotherapy
Answer: B
CORRECT ANSWER : B
Rationale: ARNIs are first-line Guideline-Directed Medical Therapy (GDMT) for HFrEF due to
their superior mortality benefit compared to ACE inhibitors. Option A is contraindicated in
HFrEF. Option C is for symptomatic relief of fluid, not mortality benefit. Option D is adjunctive,
not foundational.
4. A nurse practitioner is evaluating the patient's volume status. Which of the following findings is
most consistent with a diagnosis of fluid overload requiring aggressive diuresis?
A. Resting heart rate of 72 bpm
B. Presence of bilateral 2+ pitting edema and a positive hepatojugular reflux
C. Clear lung sounds on auscultation
D. Serum creatinine decrease from 1.2 to 0.9 mg/dL
Answer: B
CORRECT ANSWER : B
Rationale: Positive hepatojugular reflux and pitting edema are classic physical markers of
systemic venous congestion. Options A, C, and D suggest a more stable or improving clinical
picture, which does not necessitate "aggressive" diuresis.
5. Which laboratory parameter must be closely monitored when initiating spironolactone in this
patient to prevent life-threatening adverse events?
A. Serum sodium
B. Serum potassium
C. Hemoglobin A1c
D. Mean corpuscular volume
, Answer: B
CORRECT ANSWER : B
Rationale: Spironolactone is a potassium-sparing diuretic (MRA) that significantly increases the
risk of hyperkalemia, especially when combined with RAAS inhibitors. Options A, C, and D are
not the primary safety concerns regarding the initiation of this specific drug class.
6. Following the initiation of an ARNI, the patient develops a mild, dry cough. What is the most
appropriate clinical decision?
A. Immediately switch to an ACE inhibitor
B. Discontinue all neurohormonal blockade
C. Assess for other causes such as ACE inhibitor carryover or ACE-independent pathways,
as ARNI cough is less common than with ACE inhibitors
D. Start an antihistamine to treat the cough
Answer: C
CORRECT ANSWER : C
Rationale: While ACE inhibitors are notorious for dry cough due to bradykinin accumulation,
ARNIs have a lower incidence. The provider must investigate other potential causes, including
post-nasal drip or ACE inhibitor "carryover" if switched too quickly, rather than prematurely
abandoning life-saving therapy.
7. The patient’s echocardiogram shows a dilated left ventricle with global hypokinesis. What does
"global hypokinesis" signify in this patient?
A. Focal areas of myocardial infarction
B. Uniform reduction in myocardial contractility throughout the ventricle
C. Paradoxical septal motion due to bundle branch block
D. Hyper-contractile state of the apex
Answer: B
CORRECT ANSWER : B
Rationale: Global hypokinesis refers to a generalized, diffuse reduction in the heart muscle's
ability to contract. Option A would typically show regional wall motion abnormalities, not
Study: Margaret Wilson – Progressive Dyspnea,
Volume Overload, and Heart Failure with
Reduced Ejection Fraction in a 60-Year-Old
Female With Complete Solutions EXAM with
Questions and Answers/Plus a Rationale
Updated 2026 A+/Instant Download PDF
EXAM COVERAGE
1. Pathophysiology and Epidemiology of HFrEF
2. Clinical Presentation and Physical Examination Findings
3. Diagnostic Modalities: Labs, Imaging, and Hemodynamics
4. Evidence-Based Pharmacotherapy (GDMT)
5. Differential Diagnosis and Comorbidity Management
6. Acute Decompensation and Fluid Management
7. Long-term Prognostic Indicators and Risk Stratification
8. Patient Education and Self-Management Strategies
9. Arrhythmia Risk and Device Therapy Integration
10. Interprofessional Care Coordination
,1. A 60-year-old female presents with progressive orthopnea and paroxysmal nocturnal dyspnea.
Physical examination reveals jugular venous distension (JVD) to 12 cm, a displaced apical
impulse, and a third heart sound (S3). Which of the following best explains the presence of the
S3 in this patient?
A. Atrial kick against a stiff, non-compliant ventricle
B. Rapid ventricular filling into a dilated left ventricle with high filling pressures
C. Turbulent blood flow across a restricted mitral valve annulus
D. Early systolic ejection into a dilated aorta
Answer: B
CORRECT ANSWER : B
Rationale: The S3 heart sound is highly specific for volume overload and high left ventricular
end-diastolic pressures in the setting of systolic dysfunction. Option A refers to an S4, which
indicates diastolic dysfunction. Option C refers to murmurs associated with mitral stenosis, and
option D describes flow patterns not associated with S3.
2. Laboratory testing reveals an NT-proBNP of 4,500 pg/mL. How should the provider interpret
this biomarker in the context of the patient's acute presentation?
A. It confirms a primary pulmonary diagnosis of COPD exacerbation
B. It is a non-specific marker that requires immediate cardiac catheterization
C. It strongly supports a diagnosis of decompensated heart failure due to elevated
myocardial stretch
D. It is only diagnostic if the patient has a history of coronary artery disease
Answer: C
CORRECT ANSWER : C
Rationale: NT-proBNP is a gold-standard biomarker for evaluating cardiac wall stress and
volume overload. While elevation can occur in other conditions, a value of 4,500 is highly
suggestive of heart failure in this clinical context. Option A is incorrect because BNP would
typically be low in primary pulmonary disease, and D is incorrect as it is not limited to patients
with known CAD.
3. The patient is diagnosed with HFrEF (EF 30%). Which medication is indicated as foundational
therapy for its proven benefit in reducing mortality and hospitalizations in HFrEF?
, A. Calcium Channel Blockers (non-dihydropyridines)
B. Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
C. High-dose short-acting loop diuretics
D. Oral nitrates as monotherapy
Answer: B
CORRECT ANSWER : B
Rationale: ARNIs are first-line Guideline-Directed Medical Therapy (GDMT) for HFrEF due to
their superior mortality benefit compared to ACE inhibitors. Option A is contraindicated in
HFrEF. Option C is for symptomatic relief of fluid, not mortality benefit. Option D is adjunctive,
not foundational.
4. A nurse practitioner is evaluating the patient's volume status. Which of the following findings is
most consistent with a diagnosis of fluid overload requiring aggressive diuresis?
A. Resting heart rate of 72 bpm
B. Presence of bilateral 2+ pitting edema and a positive hepatojugular reflux
C. Clear lung sounds on auscultation
D. Serum creatinine decrease from 1.2 to 0.9 mg/dL
Answer: B
CORRECT ANSWER : B
Rationale: Positive hepatojugular reflux and pitting edema are classic physical markers of
systemic venous congestion. Options A, C, and D suggest a more stable or improving clinical
picture, which does not necessitate "aggressive" diuresis.
5. Which laboratory parameter must be closely monitored when initiating spironolactone in this
patient to prevent life-threatening adverse events?
A. Serum sodium
B. Serum potassium
C. Hemoglobin A1c
D. Mean corpuscular volume
, Answer: B
CORRECT ANSWER : B
Rationale: Spironolactone is a potassium-sparing diuretic (MRA) that significantly increases the
risk of hyperkalemia, especially when combined with RAAS inhibitors. Options A, C, and D are
not the primary safety concerns regarding the initiation of this specific drug class.
6. Following the initiation of an ARNI, the patient develops a mild, dry cough. What is the most
appropriate clinical decision?
A. Immediately switch to an ACE inhibitor
B. Discontinue all neurohormonal blockade
C. Assess for other causes such as ACE inhibitor carryover or ACE-independent pathways,
as ARNI cough is less common than with ACE inhibitors
D. Start an antihistamine to treat the cough
Answer: C
CORRECT ANSWER : C
Rationale: While ACE inhibitors are notorious for dry cough due to bradykinin accumulation,
ARNIs have a lower incidence. The provider must investigate other potential causes, including
post-nasal drip or ACE inhibitor "carryover" if switched too quickly, rather than prematurely
abandoning life-saving therapy.
7. The patient’s echocardiogram shows a dilated left ventricle with global hypokinesis. What does
"global hypokinesis" signify in this patient?
A. Focal areas of myocardial infarction
B. Uniform reduction in myocardial contractility throughout the ventricle
C. Paradoxical septal motion due to bundle branch block
D. Hyper-contractile state of the apex
Answer: B
CORRECT ANSWER : B
Rationale: Global hypokinesis refers to a generalized, diffuse reduction in the heart muscle's
ability to contract. Option A would typically show regional wall motion abnormalities, not
